Aptar Pharma announced that it has acquired OINDP specialist CDMO Mod3 Pharma (formerly Enteris Biopharma). According to Mod3’s web site, Enteris was created in 2013 with assets and personnel from Unigene, which manufactured Fortical calcitonin nasal spray.
In 2015, Enteris built a cGMP manufacturing facility in Boonton, New Jersey, USA. That facility now adds OINDP clinical trial supply capabilities to Aptar Pharma’s offerings, including Phase 1 and 2 cGMP OINDP fill and finish. According to Aptar, the Boonton facility is capable of handling biologics and high-potency actives.
Aptar Pharma President Gael Touya commented, “Our vision at Aptar Pharma is clear: from formulation to patient. By integrating Phase 1 and 2 clinical manufacturing capabilities, we’re not just expanding our technical footprint, we’re deepening our commitment to customers seeking a seamless and accelerated path to market. This move reinforces our position as a trusted partner from molecule to delivery, and ultimately, to the patient.”
Mod3 Pharma CEO Paul Shields said, “We are delighted to become part of the Aptar family. This acquisition reflects our shared commitment of accelerating the development of innovative therapies and bringing them to patients faster.”
Read the Aptar Pharma press release
